Broderick Brian C Reduces Position in Eli Lilly And Co (LLY)

Broderick Brian C lowered its position in Eli Lilly And Co (NYSE:LLY) by 19.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,282 shares of the company’s stock after selling 566 shares during the period. Broderick Brian C’s holdings in Eli Lilly And Co were worth $296,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in LLY. Neuberger Berman Group LLC grew its holdings in shares of Eli Lilly And Co by 4.3% during the third quarter. Neuberger Berman Group LLC now owns 1,380,456 shares of the company’s stock valued at $148,137,000 after buying an additional 57,056 shares during the last quarter. Nordea Investment Management AB grew its holdings in shares of Eli Lilly And Co by 0.4% during the third quarter. Nordea Investment Management AB now owns 418,277 shares of the company’s stock valued at $44,882,000 after buying an additional 1,674 shares during the last quarter. Morgan Stanley grew its holdings in shares of Eli Lilly And Co by 5.3% during the third quarter. Morgan Stanley now owns 4,710,695 shares of the company’s stock valued at $505,506,000 after buying an additional 237,158 shares during the last quarter. Great Lakes Advisors LLC purchased a new stake in shares of Eli Lilly And Co during the third quarter valued at $395,000. Finally, Federated Investors Inc. PA grew its holdings in shares of Eli Lilly And Co by 41.0% during the third quarter. Federated Investors Inc. PA now owns 823,717 shares of the company’s stock valued at $88,394,000 after buying an additional 239,612 shares during the last quarter. Hedge funds and other institutional investors own 79.17% of the company’s stock.

A number of brokerages have recently weighed in on LLY. BMO Capital Markets boosted their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Cantor Fitzgerald reissued a “buy” rating and set a $143.00 price objective on shares of Eli Lilly And Co in a report on Tuesday, April 30th. Edward Jones raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective on the stock in a report on Tuesday, April 23rd. Barclays reissued a “buy” rating and set a $140.00 price objective on shares of Eli Lilly And Co in a report on Sunday, April 14th. Finally, Guggenheim lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 price objective on the stock. in a report on Thursday, April 11th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Eli Lilly And Co has an average rating of “Buy” and a consensus price target of $118.83.

In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total transaction of $25,108,400.00. Following the completion of the transaction, the insider now owns 117,641,684 shares of the company’s stock, valued at approximately $14,408,753,456.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 870,959 shares of company stock valued at $109,672,752. Insiders own 0.11% of the company’s stock.

NYSE LLY opened at $115.80 on Friday. The firm has a market cap of $112.86 billion, a P/E ratio of 20.86, a price-to-earnings-growth ratio of 2.07 and a beta of 0.27. Eli Lilly And Co has a 1 year low of $79.41 and a 1 year high of $132.13. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.01. The company had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.31 earnings per share. On average, equities analysts predict that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Friday, May 17th will be given a $0.645 dividend. The ex-dividend date is Thursday, May 16th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.23%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.

TRADEMARK VIOLATION NOTICE: This news story was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/broderick-brian-c-reduces-position-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: What is Compound Interest?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.